Target intelligence / Profile preview

Cysteine-rich secretory protein 1 (CRISP1)

Target
CRISP1
Molecular classification
Cysteine-rich secretory protein (CRISP) family, CAP superfamily (includes Cysteine-rich secretory protein, Antigen-5, Pathogenesis Related-1 proteins), Ion channel regulator, Secreted glycoprotein
01

Overview

Cysteine-rich secretory protein 1 (CRISP1) is a member of the CRISP family, characterized by 16 conserved cysteine residues and a modular structure including a signal peptide, an N-terminal CAP domain, a hinge region, and a C-terminal cysteine-rich domain (CRD). It is predominantly expressed in the epididymis and secreted into the lumen, where it binds to sperm with two affinities: a loosely bound pool acts as a decapacitation factor and is released during capacitation, while a tightly bound pool remains on sperm for sperm-egg binding and fusion. CRISP1 modulates gamete interactions, sperm motility, and orientation via channel regulation (CatSper and TRPM8), playing a key role in fertilization. Knockouts reveal non-essential but supportive roles in fertility and possible redundancy by other CRISP family members. CRISP1 is proposed as a target for male contraception. Mutations have indirect links to genetic syndromes such as ectodermal dysplasia. No approved drugs target CRISP1 directly.

Other names
AEGL1CRISP-1ARPHUMARPHSCRISP1DHSCRISP1GAEG-like proteinAcidic epididymal glycoprotein homologepididymis secretory protein Li 57HEL-S-57
02

Mechanism of action

Physiological inhibitor/blocker of CatSper sperm calcium channel; Modulation of TRPM8 calcium channel activity; Decapacitation factor: prevents premature capacitation by inhibiting signaling cascades in sperm

03

Biological functions

Sperm-egg fusionDecapacitation/regulation of sperm capacitationRegulation of ion channels (CatSper, TRPM8)Sperm motility and orientationCell-cell adhesionFertilization
04

Disease associations

Male infertility (gene knockout and mutations can affect sperm function)Ectodermal dysplasia (where CRISP1 mutations are implicated; hair/nail types)
05

Safety considerations

Not well described for therapeutic intervention. Targeting for contraception may carry risks associated with impaired fertility
06

Biomarkers

Not established for direct patient selection or efficacy monitoring in clinical studies. Implicated in fertility assessments

Beyond the preview

Go deeper on Cysteine-rich secretory protein 1 (CRISP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cysteine-rich secretory protein 1 (CRISP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call